Senzar Asset Management Llc Trimmed Aerie Pharmaceuticals Inc (NASDAQ:AERI) Position by $11.22 Million as Price Declined

May 17, 2018 - By Alberto Lyles

During 2017 Q4 the big money sentiment decreased to 1.2. That’s change of 0.53, from 2017Q3’s 1.73. 23 investors sold all, 48 reduced holdings as AERI ratio dropped. 64 grew positions while 21 funds bought positions. Funds hold 34.86 million shares thus 1.29% more from 2017Q3’s 34.42 million shares. Partner Fund Mgmt Limited Partnership has 3.69% invested in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). 45,223 were accumulated by Castleark Management Limited Liability Co. Wells Fargo Mn owns 22,991 shs for 0% of their capital. Meeder Asset Incorporated has 3 shs. Deutsche Bank Ag invested 0% of its capital in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Thrivent For Lutherans, a Minnesota-based fund reported 106,900 shs. Brown Brothers Harriman And Communications, a New York-based fund reported 113 shs. Manchester Management Ltd Liability Co holds 0% or 150 shs in its capital. United Capital Fin Advisers Limited Liability Company stated it has 0% of its capital in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Polar Ltd Liability Partnership accumulated 100,000 shs. 45,366 are owned by Endurant Mngmt L P. Comml Bank Of New York Mellon owns 613,305 shs for 0.01% of their capital. Moreover, Pictet Asset has 0.05% invested in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) for 318,164 shs. Partner Inv Mngmt Limited Partnership invested in 33,688 shs or 2.32% of the stock. Sei Invs invested in 0% or 4,140 shs.

Senzar Asset Management Llc reduced its holdings by 74.62% in Aerie Pharmaceuticals Inc (NASDAQ:AERI), according to 2018Q1 SEC filling. By selling 207,732 shares Senzar Asset Management Llc made the stock Sank with 12.77%. The health care company announced $3.83 million value for the 2018Q1. Now the hedge fund is holding 70,668 shares, compared to the 278,400 from the previous quarter. $2.02B is the market cap of Aerie Pharmaceuticals Inc. AERI reached $51.2 during the last trading session after $0.8 change.Currently Aerie Pharmaceuticals, Inc. is uptrending after 16.25% change in last May 17, 2017. AERI has 224,990 shares volume. The stock outperformed the S&P 500 by 4.70%.

Senzar Asset Management Llc has risen its stake in and also increased its holding in by shares in the quarter, for a total of shares.

Senzar Asset Management Llc is a New York-based hedge fund with more than $442.00 million AUM in December, 2014. Taken from Senzar Asset Management latest Adv, the fund reported to have 7 full and part-time employees. Among which 4 performing investment advisory and research functions. The hedge fund had between 1-10 clients.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Ratings Coverage

In total 6 analysts cover Aerie Pharma (NASDAQ:AERI). “Buy” rating has 6, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 11 are the (NASDAQ:AERI)’s analyst reports since December 18, 2017 according to StockzIntelligence Inc. On Wednesday, January 24 the rating was maintained by Canaccord Genuity with “Buy”. In Friday, February 16 report H.C. Wainwright reinitiated the stock with “Buy” rating. On Wednesday, February 28 Cantor Fitzgerald maintained the shares of AERI in report with “Buy” rating. On Thursday, March 29 the firm has “Buy” rating by Mizuho given. On Wednesday, May 9 the rating was maintained by Mizuho with “Buy”. On Wednesday, May 9 the firm has “Buy” rating given by H.C. Wainwright. On Thursday, March 1 the stock of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) has “Buy” rating given by H.C. Wainwright. On Tuesday, May 8 the firm earned “Buy” rating by Cantor Fitzgerald. On Monday, December 18 the stock of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) has “Buy” rating given by Cantor Fitzgerald. The stock rating was maintained by Stifel Nicolaus with “Buy” on Tuesday, January 2.

Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases.The firm is worth $2.02 billion. The Company’s lead product candidate includes Rhopressa, a once-daily eye drop for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension.Currently it has negative earnings. The firm is also developing Roclatan, a once-daily eye drop to reduce IOP that is in Phase III registration trials to treat patients with open-angle glaucoma and ocular hypertension.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: